


**Claim amendments:**

1. – 43. (cancelled)

44. (currently amended) A compound of the formula:



where:

each of W, X and Y is independently CR<sup>6</sup>R<sup>7</sup>, N-R<sup>7</sup>, O, or S, provided that at least one of W, X, and Y contains a non-carbon ring atom, and at least one of W, X, and Y contains a carbon ring atom;

Z is N or C-R<sup>8</sup>;

each of R<sup>1</sup>, R<sup>2</sup>, R<sup>6</sup>, and R<sup>8</sup> is independently hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted

heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), -CF<sub>3</sub>, halogen, nitro, -CN, -OR<sup>9</sup>, -SR<sup>9</sup>,

-NR<sup>9</sup>R<sup>10</sup>, -NR<sup>9</sup>(carboxy(lower alkyl)), -C(=O)R<sup>9</sup>, -C(=O)OR<sup>9</sup>, -C(=O)NR<sup>9</sup>R<sup>10</sup>,

-OC(=O)R<sup>9</sup>, -SO<sub>2</sub>R<sup>9</sup>, -OSO<sub>2</sub>R<sup>9</sup>, -SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>,

-NR<sup>9</sup>SO<sub>2</sub>R<sup>10</sup>, or -NR<sup>9</sup>C(=O)R<sup>10</sup>, where R<sup>9</sup> and R<sup>10</sup> are independently hydrogen,

optionally substituted lower alkyl, lower alkyl-N(C<sub>1-2</sub> alkyl)<sub>2</sub>, lower alkyl(optionally

substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl,

cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower

alkyl), optionally substituted aryl, optionally substituted heteroaryl, or heteroaryl(lower

alkyl), or R<sup>9</sup> and R<sup>10</sup> together are -(CH<sub>2</sub>)<sub>4-6</sub>- optionally interrupted by one O, S, NH,

N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C<sub>1-2</sub> alkyl) group;

R<sup>3</sup> and R<sup>4</sup> are independently hydrogen or lower alkyl or together are -(CH<sub>2</sub>)<sub>4-6</sub>-;

each R<sup>7</sup> is independently hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally

substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl),  $-C(=O)R^9$ ,  $-C(=O)OR^9$ ,  $-C(=O)NR^9R^{10}$ ,  $-SO_2R^9$ , or  $-SO_2NR^9R^{10}$ , where  $R^9$  and  $R^{10}$  are independently hydrogen, optionally substituted lower alkyl, lower alkyl- $N(C_{1-2} \text{ alkyl})_2$ , lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, or heteroaryl(lower alkyl), or  $R^9$  and  $R^{10}$  together are  $-(CH_2)_{4-6}$  optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)), or N-(optionally substituted  $C_{1-2}$  alkyl) group;  $R^{13}$  is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl),  $-CF_3$ , halo(lower alkyl), halogen, nitro,  $-CN$ ,  $-OR^{15}$ ,  $-SR^{15}$ ,  $-NR^{15}R^{16}$ ,  $-C(=O)R^{15}$ ,  $-C(=O)OR^{15}$ ,  $-C(=O)NR^{15}R^{16}$ ,  $-OC(=O)R^{15}$ ,  $-SO_2R^{15}$ ,  $-SO_2NR^{15}R^{16}$ ,  $-NR^{15}SO_2R^{16}$ , or  $-NR^{15}C(=O)R^{16}$ , where  $R^{15}$  and  $R^{16}$  are independently hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl,  $-CF_3$ , cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heteroaryl(lower alkyl), or together are  $-(CH_2)_{4-6}$  optionally interrupted by one O, S, NH or N-( $C_{1-2}$  alkyl) group; each  $R^{14}$  is independently optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen,  $-CF_3$ ,  $-OR^{17}$ ,  $-NR^{17}R^{18}$ ,  $-C(=O)R^{17}$ ,  $-C(=O)OR^{17}$ ,  $-O(CH_2)_mC(=O)OR^{17}$ , where  $m$  is an integer of 1 to 4, or  $-C(=O)NR^{17}R^{18}$ , where  $R^{17}$  and  $R^{18}$  are independently, hydrogen, lower alkyl, alkenyl, alkynyl,  $-CF_3$ , optionally substituted heterocycloalkyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl) or, together, are  $-(CH_2)_{4-6}$ , optionally interrupted by one O, S, NH or N-( $C_{1-2}$  alkyl) group; and  $n$  is an integer of 0 to 4; or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

45. (previously presented) The compound of claim 44, where W and Y are O, X is  $\text{CR}^6\text{R}^7$ , where  $\text{R}^6$  and  $\text{R}^7$  are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is C-H.

46. (previously presented) The compound of claim 44, where W and X are each  $\text{CR}^6\text{R}^7$ , where  $\text{R}^6$  and  $\text{R}^7$  are independently hydrogen, lower alkyl, or optionally substituted aryl, Y is O, and Z is C-H.

47. (previously presented) The compound of claim 44, where W is O, X and Y are each  $\text{CR}^6\text{R}^7$ , where  $\text{R}^6$  and  $\text{R}^7$  are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is C-H.

48. (previously presented) The compound of claim 44, where W and X are each  $\text{CR}^6\text{R}^7$ , where  $\text{R}^6$  and  $\text{R}^7$  are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is N.

49. (previously presented) The compound of claim 44, where W is  $\text{CR}^6\text{R}^7$ , where  $\text{R}^6$  and  $\text{R}^7$  are independently hydrogen, lower alkyl, or optionally substituted aryl, X is O, and Z is N.

50. (previously presented) The compound of claim 44, where W is O, X is  $\text{CR}^6\text{R}^7$ , where  $\text{R}^6$  and  $\text{R}^7$  are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is N.

51. (previously presented) The compound of claim 44, where  $\text{R}^1$  is hydrogen, optionally substituted lower alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen,  $-\text{OR}^9$ ,  $-\text{NR}^9[\text{carboxy(lower alkyl)}]$ ,  $-\text{C}(=\text{O})\text{OR}^9$ ,  $-\text{C}(=\text{O})\text{NR}^9\text{R}^{10}$ ,  $-\text{SO}_2\text{NR}^9\text{R}^{10}$ , or  $-\text{NR}^9\text{C}(=\text{O})\text{R}^{10}$ , where  $\text{R}^9$  and  $\text{R}^{10}$  are independently hydrogen, optionally substituted lower alkyl, lower alkyl- $\text{N}(\text{C}_{1-2} \text{ alkyl})_2$ , lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl), or  $\text{R}^9$  and  $\text{R}^{10}$

together are  $-(CH_2)_{4-6}-$  optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted  $C_{1-2}$  alkyl) group.

52. (previously presented) The compound of claim 44, where  $R^2$  is hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), halogen,  $-OR^9$ ,  $-NR^9R^{10}$ ,  $-C(=O)OR^9$ , or  $-C(=O)NR^9R^{10}$ , where  $R^9$  and  $R^{10}$  are independently hydrogen, optionally substituted lower alkyl, lower alkyl- $N(C_{1-2}$  alkyl) $_2$ , lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl), or  $R^9$  and  $R^{10}$  together are  $-(CH_2)_{4-6}-$  optionally interrupted by one O, S, NH, N-(aryl), N-[aryl(lower alkyl)], N-(carboxy(lower alkyl)) or N-(optionally substituted  $C_{1-2}$  alkyl) group.

53. (previously presented) The compound of claim 44 where  $R^3$  and  $R^4$  are independently hydrogen or lower alkyl.

54. (previously presented) The compound of claim 44, where  $R^6$  and  $R^7$  are independently hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl),  $-C(=O)R^9$ ,  $-C(=O)OR^9$ ,  $-C(=O)NR^9R^{10}$ ,  $-SO_2R^9$ , or  $-SO_2NR^9R^{10}$ , where  $R^9$  and  $R^{10}$  are independently, hydrogen, optionally substituted lower alkyl, lower alkyl- $N(C_{1-2}$  alkyl) $_2$ , alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, or heteroaryl(lower alkyl).

55. (previously presented) The compound of claim 44, where  $R^8$  is hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl),  $-CF_3$ , halogen,  $-OR^9$ ,  $-NR^9R^{10}$ ,  $-C(=O)R^9$ ,  $-C(=O)OR^9$ ,  $-C(=O)NR^9R^{10}$ ,  $-OC(=O)R^9$ ,  $-SO_2R^9$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{10}$  or  $-NR^9C(=O)R^{10}$ , where  $R^9$  and  $R^{10}$  are independently, hydrogen,

optionally substituted lower alkyl, lower alkyl-N(C<sub>1-2</sub> alkyl)<sub>2</sub>, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R<sup>9</sup> and R<sup>10</sup> together are -(CH<sub>2</sub>)<sub>4-6</sub>- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C<sub>1-2</sub> alkyl) group.

56. (previously presented) The compound of claim 44, where R<sup>1</sup> and R<sup>2</sup> are independently hydrogen, lower alkyl, halogen, optionally lower alkyl substituted heterocycloalkyl, -OR<sup>9</sup>, -SR<sup>9</sup>, or -NR<sup>9</sup>R<sup>10</sup>, where R<sup>9</sup> and R<sup>10</sup> are hydrogen, lower alkyl or optionally substituted aryl.

57. (previously presented) The compound of claim 44, where R<sup>1</sup>, R<sup>2</sup>, and R<sup>8</sup> are independently optionally substituted lower alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, -OR<sup>9</sup>, -NR<sup>9</sup>[carboxy(lower alkyl)], -C(=O)OR<sup>9</sup>, -C(=O)NR<sup>9</sup>R<sup>10</sup>, -SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, or -NR<sup>9</sup>C(=O)R<sup>10</sup>, where R<sup>9</sup> and R<sup>10</sup> are independently, hydrogen, lower alkyl, or R<sup>9</sup> and R<sup>10</sup> together are -(CH<sub>2</sub>)<sub>4-6</sub>- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C<sub>1-2</sub> alkyl) group.

58. (previously presented) The compound of claim 44, where R<sup>1</sup>, R<sup>3</sup>, and R<sup>4</sup> are hydrogen.

59. (previously presented) The compound of claim 44, where R<sup>13</sup> is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), -CF<sub>3</sub>, halogen, nitro, -CN, -OR<sup>15</sup>, -SR<sup>15</sup>, -NR<sup>15</sup>R<sup>16</sup>, -C(=O)R<sup>15</sup>, -C(=O)OR<sup>15</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>, or -NR<sup>15</sup>C(=O)R<sup>16</sup>, where R<sup>15</sup> and R<sup>16</sup> are independently hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, or halo(lower alkyl).

60. (previously presented) The compound of claim 44, where R<sup>13</sup> is alkynyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, -CF<sub>3</sub>, -CN, -OR<sup>15</sup>,

-C(=O)R<sup>15</sup>, -C(=O)OR<sup>15</sup>, or -C(=O)NR<sup>15</sup>R<sup>16</sup>, where R<sup>15</sup> and R<sup>16</sup> are independently, hydrogen, lower alkyl, halo(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl) or R<sup>15</sup> and R<sup>16</sup> together are -(CH<sub>2</sub>)<sub>4-6</sub>-, optionally interrupted by one O, S, NH or N-(C<sub>1-2</sub> alkyl) group.

61. (previously presented) The compound of claim 44, where each R<sup>14</sup> is independently optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, -CF<sub>3</sub>, -OR<sup>17</sup>, -NR<sup>17</sup>R<sup>18</sup>, -C(=O)R<sup>17</sup>, -C(=O)OR<sup>17</sup>, -O(CH<sub>2</sub>)<sub>m</sub>C(=O)OR<sup>17</sup>, where m is an integer of 1 to 4, or -C(=O)NR<sup>17</sup>R<sup>18</sup>, where R<sup>17</sup> and R<sup>18</sup> are, independently, hydrogen, lower alkyl, alkenyl, or optionally substituted aryl.

62. (previously presented) The compound of claim 44, where each R<sup>14</sup> is independently halogen, -CF<sub>3</sub>, -OR<sup>17</sup>, -C(=O)OR<sup>17</sup>, -O(CH<sub>2</sub>)<sub>m</sub>C(=O)OR<sup>17</sup>, where m is an integer of 1 to 4, or -C(=O)NR<sup>17</sup>R<sup>18</sup>, where R<sup>17</sup> and R<sup>18</sup> are independently, hydrogen, lower alkyl, optionally substituted aryl, heteroaryl, or heteroaryl(lower alkyl), or R<sup>17</sup> and R<sup>18</sup> together are -(CH<sub>2</sub>)<sub>4-6</sub>-, optionally interrupted by one O, S, NH or N-(C<sub>1-2</sub> alkyl) group.

63. (previously presented) The compound of claim 44 where R<sup>13</sup> is not hydrogen and n is 1 or 2.

64. (previously presented) The compound of claim 63 where n is 1.

65. (previously presented) The compound of claim 44 that is selected from:

2H-benzo[d]1,3-dioxolan-5-yl-N- {[ (3-chloro-4-hydroxyphenyl)amino]carbonyl}-carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N- {[ (3,4-dichlorophenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N- ([ (2,6-bis(methylethyl)phenyl)amino]carbonyl)-carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N- {[ (4-hydroxyphenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N- {[ (3-chloro-4-methoxyphenyl)amino]carbonyl}-

carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-{{[(3-chlorophenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-[(phenylamino)carbonyl]carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[(5-chloro-2-hydroxyphenyl)amino]carbonyl}-  
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[(3-fluorophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[(2,6-difluorophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[(2,3-difluorophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[(4-fluorophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[(4-chlorophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[(3,4-difluorophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[4-(trifluoromethyl)phenyl]amino}carbonyl)-  
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-(trifluoromethyl)phenyl]amino}carbonyl)-  
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[(4-nitrophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[4-nitro-3-(trifluoromethyl)phenyl]amino}-  
carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[4-chloro-3-(trifluoromethyl)phenyl]amino}-  
carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[(4-bromophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[(3-bromophenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-{{[(3-cyanophenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-{{[(2,4-dichlorophenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-{{[(4-methoxyphenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-{{[(4-iodophenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-{{[(3-iodophenyl)amino]carbonyl}carboxamide;

4-{{[(2H-benzo[d]1,3-dioxolan-5-ylcarbonylamino)carbonyl]amino}benzamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-({[3-fluoro-4-(trifluoromethyl)phenyl]amino}carbonyl)-  
carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-({[4-fluoro-3-(trifluoromethyl)phenyl]amino}carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[4-phenylphenyl]amino}carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-(trifluoromethoxy)phenyl]amino}carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-(trifluoromethylthio)phenyl]amino}carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3,5-bis(trifluoromethyl)phenyl]amino}carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-(methylethyl)phenyl]amino}carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-ethylphenyl]amino}carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-ethoxyphenyl]amino}carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-(methylethoxy)phenyl]amino}carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-(tert-butyl)phenyl]amino}carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-phenylphenyl]amino}carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-chloro-4-methylphenyl]amino}carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-iodo-4-methylphenyl]amino}carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[4-methyl-3-(trifluoromethyl)phenyl]amino}-carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-phenoxyphenyl]amino}carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-nitrophenyl]amino}carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3,5-dichlorophenyl]amino}carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-acetylphenyl]amino}carbonyl)carboxamide;

methyl 3-({[(2H-benzo[3,4-d]1,3-dioxolen-5-ylcarbonylamino)carbonyl]amino}benzoate;



2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-(1H-1,2,3,4-tetraazol-5-yl)phenyl)amino]-  
carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-ethynylphenyl)amino]carbonyl} carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-chloro-2-methylphenyl)amino]carbonyl}-  
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(5-chloro-2-methylphenyl)amino]carbonyl}-  
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-chloro-2,6-diethylphenyl)amino]carbonyl} -  
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(5-iodo-2-methylphenyl)amino]carbonyl}-  
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-(2-pyridyl)phenyl)amino]carbonyl}-  
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-(1,3-thiazol-2-yl)phenyl)amino]carbonyl}-  
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-(3-thienyl)phenyl)amino]carbonyl}-  
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-(2-furyl)phenyl)amino]carbonyl} carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-(2-thienyl)phenyl)amino]carbonyl}-  
carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N- {[(3-icyanophenyl)amino]carbonyl}-  
carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N- {[(3-iodophenyl)amino]carbonyl}-  
carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N- ( { [3-(trifluoromethyl)phenyl]amino } -  
carbonyl)carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N- ( { [3-(methylethoxy)phenyl]amino } -  
carbonyl)carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N- ( { [4-fluoro-3-(trifluoromethyl)phenyl]-  
amino } carbonyl) carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{{(3-chlorophenyl)methylamino}carbonyl}-N-methylcarboxamide;  
2H-benzo[d]1,3-dioxolan-5-yl-N-{{{(3-chlorophenyl)amino}carbonyl}-N-methylcarboxamide;  
N-{{{(3,4-dichlorophenyl)amino}carbonyl}-2,3-dihydrobenzo[b]furan-5-ylcarboxamide;  
N-{{{(3-chlorophenyl)amino}carbonyl}-2,3-dihydrobenzo[b]furan-5-ylcarboxamide;  
2,3-dihydrobenzo[b]furan-5-yl-N-({[4-(trifluoromethyl)phenyl]amino}carbonyl)-carboxamide;  
2,3-dihydrobenzo[b]furan-5-yl-N-({[4-fluorophenyl]amino}carbonyl}carboxamide; and  
2,3-dihydrobenzo[b]furan-5-yl-N-({[4-methoxyphenyl]amino}carbonyl}carboxamide;  
and the pharmaceutically acceptable salts thereof, as single stereoisomers or mixtures of stereoisomers.

66. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 44 and a pharmaceutically acceptable excipient.

67. (previously presented) The pharmaceutical composition of claim 66, further comprising an anti-inflammatory drug, cytokine, or immunomodulator.

68. (previously presented) A method of treating an allergic, inflammatory, or autoimmune disorder or disease, comprising administering a therapeutically effective amount of a compound of claim 44 to a mammal in need of such treatment.

69. (previously presented) The method of claim 68 where the compound is administered in combination with an anti-inflammatory drug, cytokine, or immunomodulator.

70. (previously presented) The method of claim 68 where the allergic, inflammatory, or autoimmune disorder or disease is selected from the group consisting of asthma, atherosclerosis, glomerulonephritis, pancreatitis, restenosis, rheumatoid arthritis, diabetic nephropathy, pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, and transplant rejection.

71. (previously presented) The method of claim 68 where the allergic, inflammatory, or autoimmune disorder or disease is associated with lymphocyte and/or monocyte accumulation.

72. (previously presented) A method of inhibiting leukocyte migration, comprising administering a therapeutically effective amount of a compound of claim 44 to a mammal in need of such treatment.